Mecamylamine ophthalmic - CoMentis

Drug Profile

Mecamylamine ophthalmic - CoMentis

Alternative Names: ATG 003; ATG-3

Latest Information Update: 15 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CoMentis
  • Class Eye disorder therapies; Norbornanes; Small molecules
  • Mechanism of Action Nicotinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Age-related macular degeneration; Diabetic macular oedema

Most Recent Events

  • 30 Sep 2007 Phase-II clinical trials in Diabetic macular oedema in USA (Ophthalmic)
  • 10 Apr 2007 Phase-II clinical trials in Age-related macular degeneration in Brazil (Ophthalmic)
  • 06 Mar 2007 Results from a phase I clinical trial involving healthy volunteers added to the adverse events section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top